 |
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide |
|---|---|
| Trade Name | |
| Orphan Indication | Tardive dyskinesia |
| USA Market Approval | USA |
| USA Designation Date | 2003-07-03 00:00:00 |
| Sponsor | Phase 2 Discovery, Inc.;3130 Highland Ave., Third Floor;Cincinnati, Ohio, 45219 |
